Dose-finding Study in Platinum-Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
- Dose-finding study of GSK2110183 administered in combination with carboplatin and
paclitaxel to any subject with recurrent ovarian cancer.
- Safety and efficacy study of GSK2110183 administered in combination with carboplatin and
paclitaxel to subjects with platinum-resistant ovarian cancer.